| P50 | author | Jerome Robert | Q56858042 |
| | Aurélie Chauffour | Q88580413 |
| P2093 | author name string | Vincent Jarlier | |
| | Kevin Pethe | |
| | Alexandra Aubry | |
| | Nicolas Veziris | |
| P2860 | cites work | Delayed versus standard assessment for excision surgery in patients with Buruli ulcer in Benin: a randomised controlled trial. | Q54244183 |
| | Targeting the Mycobacterium ulcerans cytochrome bc:aa for the treatment of Buruli ulcer | Q60020041 |
| | Oral Treatment for Mycobacterium ulcerans Infection: Results From a Pilot Study in Benin | Q61479399 |
| | Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial | Q90325404 |
| | Buruli ulcer treatment: Rate of surgical intervention differs highly between treatment centers in West Africa | Q90970892 |
| | Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay | Q91623033 |
| | Towards a new combination therapy for tuberculosis with next generation benzothiazinones | Q27681604 |
| | Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis | Q28486345 |
| | In-vitro activity of avermectins against Mycobacterium ulcerans | Q28543887 |
| | Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment | Q28547238 |
| | Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease | Q28552524 |
| | Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice | Q28552736 |
| | Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. | Q30352594 |
| | Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice | Q34144367 |
| | Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid | Q34658779 |
| | In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. | Q34680628 |
| | Potent twice-weekly rifapentine-containing regimens in murine tuberculosis | Q35776635 |
| | Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis | Q35806445 |
| | Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model | Q36364009 |
| | Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains | Q36558371 |
| | Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice | Q36703065 |
| | Tedizolid (TR-701): a new oxazolidinone with enhanced potency | Q37983130 |
| | Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic | Q38536296 |
| | Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages | Q38749324 |
| | THE EXPERIMENTAL DISEASE THAT FOLLOWS THE INJECTION OF HUMAN LEPROSY BACILLI INTO FOOT-PADS OF MICE. | Q41861671 |
| | Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp- deficient knockout mice | Q46152205 |
| | DprE1, a new taxonomic marker in mycobacteria | Q48037784 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P921 | main subject | Mycobacterium ulcerans | Q141154 |
| P304 | page(s) | e0007857 | |
| P577 | publication date | 2020-08-31 | |
| P1433 | published in | PLoS Neglected Tropical Diseases | Q3359737 |
| P1476 | title | Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses | |
| P478 | volume | 14 | |